双重打击弥漫性大B细胞淋巴瘤的临床病理研究进展  

Research progress on clinical pathology for double-hit diffuse large B-cell lymphoma

作　　者：刘娟[1,2] 徐钢[2] 王晓卿[2] 

机构地区：[1]遵义医学院,贵州省遵义市563000 [2]四川省医学科学院四川省人民医院病理科

出　　处：《中国肿瘤临床》2016年第12期536-540,共5页Chinese Journal of Clinical Oncology

摘　　要：弥漫性大B细胞淋巴瘤（diffuse large B-cell lymphoma,DLBCL）是一种具有高度异质性的淋巴造血系统恶性肿瘤,目前用标准化疗方案治疗的多数DLBCL患者可以被治愈,但仍有30%~40%的DLBCL患者治疗后复发或难以治愈而死亡。双重打击淋巴瘤（double-hit lymphoma,DHL）主要发生于DLBCL及介于DLBCL和伯基特淋巴瘤（Burkitt＇s lymphoma,BL）之间无法分类的B细胞淋巴瘤（B-cell lymphoma unclassifiable with features intermediate between DLBCL and Burkitt＇s lymphoma,BCLU）为生存期短、预后差、易复发的一种独特类型,是近年来的研究热点。虽然BCLU更容易发生DHL,但DLBCL是DHL最常见的淋巴瘤,因此本文旨在对双重打击弥漫性大B细胞淋巴瘤（double hit-DLBCL,DH-DLBCL）的流行病学和临床特征、诊断、分子遗传学及其治疗和预后特点等方面进行综述。Diffuse large B-cell lymphoma（DLBCL） is a highly heterogeneous malignant tumor in lymphatic and hematopoietic systems.The majority of the DLBCL patients can be cured with standard chemotherapy, but around 30% to 40% of these patients can suffer from relapse and die from the disease. Double- hit lymphoma（DHL） is an unclassifiable tumor that mainly forms in DLBCL and B- cell lymphoma. The features of this tumor resemble those of DLBCL and Burkitt＇s lymphoma（BCLU）, including short survival time, poor prognosis, and easy relapse. Given these unique characteristics, DHL has attracted much research attention over the years. Although BCLUs are more prone to DHL, DLBCL is the most common lymphoma in DHL. Accordingly, this review focuses on the epidemiology,clinical characteristics, diagnosis, molecular genetics, treatment, and prognosis of double-hit DLBCL.

关 键 词：双重打击 弥漫性大B细胞淋巴瘤 分子遗传学 治疗 预后 

分 类 号：R733.1[医药卫生—肿瘤]